Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. lowered its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 49.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 26,907 shares of the company's stock after selling 25,944 shares during the period. Principal Financial Group Inc.'s holdings in Kiniksa Pharmaceuticals were worth $532,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in KNSA. Quarry LP purchased a new position in Kiniksa Pharmaceuticals during the 3rd quarter worth $50,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Kiniksa Pharmaceuticals by 12.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company's stock worth $174,000 after buying an additional 1,004 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Kiniksa Pharmaceuticals in the 3rd quarter valued at about $189,000. GSA Capital Partners LLP purchased a new stake in Kiniksa Pharmaceuticals during the 3rd quarter valued at approximately $268,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Kiniksa Pharmaceuticals during the 3rd quarter worth approximately $354,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Wedbush reissued an "outperform" rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals in a report on Tuesday, February 25th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $36.60.

Remove Ads

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other news, COO Eben Tessari sold 14,000 shares of the business's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $19.57, for a total transaction of $273,980.00. Following the sale, the chief operating officer now owns 81,975 shares of the company's stock, valued at $1,604,250.75. The trade was a 14.59 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 54.57% of the stock is owned by corporate insiders.

Kiniksa Pharmaceuticals Stock Down 3.0 %

NASDAQ KNSA traded down $0.65 during trading hours on Monday, hitting $20.86. 672,986 shares of the stock were exchanged, compared to its average volume of 404,853. The company has a market cap of $1.52 billion, a price-to-earnings ratio of -148.99 and a beta of 0.48. Kiniksa Pharmaceuticals, Ltd. has a 12-month low of $16.56 and a 12-month high of $28.15. The stock has a 50-day moving average of $19.79 and a 200 day moving average of $22.30.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $122.50 million during the quarter, compared to analyst estimates of $123.42 million. During the same period in the prior year, the business earned $0.35 earnings per share. The firm's quarterly revenue was up 46.9% compared to the same quarter last year. On average, equities research analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.